Shots:

• Bicycle to receive $1.7B including $30M upfront- development & commercialization milestones and royalties on sales of Bicycle based immuno-oncology therapies against multiple targets which will be commercialized by Genentech
• Bicycle will conduct discovery research and early pre-clinical development phase up to candidate selection while Genentech will further develop and commercialize the therapies- post-selection of candidates
• The collaboration leverages Bicycle’s discovery platform and the expertise of both the companies to identify novel therapies for multiple immuno-oncology targets

Click here ­to­ read full press release/ article | Ref: Business wire | Image: Genentech